Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IT stocks lead among gainers
Wed, 17 Sep 11:30 am

After opening firm, the benchmark Indian indices have continued to trade strong during the morning trading session. Majority of sectoral indices are trading in green with software and realty stocks being the leading gainers in the pack.

The BSE-Sensex is trading up 134 points. The NSE-Nifty is trading up 42 points. The BSE Mid Cap index is trading down 0.10% while the BSE Small Cap index is trading up 0.39%. The rupee is trading at 61.10 to the US dollar.

Most software stocks are trading higher today. Infosys and Wipro are leading the gainers. As per a leading business daily, India's second largest software firm Infosys, has begun working with top Japanese retailer Muji, to develop an interactive software platform for its 2 m customers. Infosys will deploy its proprietary platform InteractEdge, to help the retailer realise real-time insights into consumer behavior. Muji has nearly 600 retail stores in Japan and is looking to enhance its online presence. InteractEdge will help the firm generate higher sales through personalised product recommendations by understanding its customer's preferences better. The financial details of this transaction were not disclosed. Japan is currently not a big market for Infosys but the IT firm is looking to expand its presence in the country. Infosys is currently trading up 1.6%.

Majority of Indian pharma stocks are trading firm with Dishman pharma and Biocon Ltd being among the leading gainers in the pack. As per the financial daily, multinational American drug maker Gilead has entered into alliance with pharma companies to sell hepatitis generics in 90 countries. The company has signed deal with Zydus Cadila, Cipla, Strides Acrolab, Hetero, Mylan. Reportedly, Since Gilead has applied for a patent on these drugs in many countries, including India. The deal is seen as its strategic move to leverage the drugs' potential, as well as save its patent protection, which is under attack in many countries. Gilead has given rights to these companies to sell its new hepatitis C medicines sofosbuvir and ledipasvir at lower prices. Cipla has also been given exclusive API supply rights. The domestic companies are expected to benefit from this deal.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "IT stocks lead among gainers". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.